IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024. Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:30 a.m. ET. A live webcast of the presentation will be available on the Edwards Lifesciences investor ...
Edwards Lifesciences reported fourth-quarter profit on Tuesday that beat Wall Street estimates, helped by strong demand for the company's artificial heart valves and other devices.
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company's EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR). The EVOQUE system is indicated for the improvement of health status in patients with symptomatic sever...
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2023 after the market closes on Tuesday, February 6, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live ...
Edwards Lifesciences is down 3.10% over the last year but I am bullish due to its optimistic outlook and growth initiatives. The company is committed to its shareholders through EPS growth and share buyback program. EW stock is undervalued with a double-digit upside potential, warranting a buy rating.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.